Cure8 research brief
Obesity is increasingly common in people with IBD and can affect disease course, treatment response, and surgical risk.
Endoscopic bariatric therapies could fill a treatment gap between drugs and surgery but have little direct evidence in IBD, so understanding selection and monitoring is important for patients and clinicians.
Adult patients with IBD and obesity, IBD clinicians (gastroenterologists, IBD surgeons), bariatric endoscopists, nutritionists/dietitians, and researchers designing prospective studies or registries.
This review summarizes the limited evidence and practical considerations for using endoscopic bariatric therapies (EBTs) — such as intragastric balloons and endoscopic sleeve gastroplasty — in people with IBD and obesity.
It highlights candidate selection criteria (favoring sustained clinical/endoscopic remission and stable nutrition), lists conditions that raise concern (active upper-GI Crohn’s, stricturing/penetrating disease, recent surgery, severe malnutrition, sarcopenia, high-dose steroids), and recommends structured follow-up to monitor nutrition, body composition, procedural symptoms, and possible IBD activity.
The paper is a narrative review drawing mainly on general bariatric endoscopy and bariatric surgery literature because direct evidence in IBD is very limited. It proposes research priorities including prospective registries, phenotype-stratified cohorts, and comparative trials.
Practical takeaways in plain language: For people with IBD and obesity, some endoscopic weight-loss procedures might be an option but are not yet supported by strong IBD-specific data.
Doctors will likely consider disease stability, nutritional status, and surgical history before recommending EBTs, and careful post-procedure nutritional and disease monitoring is important.
This article is a narrative review (abstract-level summary provided) that synthesizes evidence largely from non-IBD bariatric endoscopy and bariatric surgery studies; direct IBD-specific data are scarce. Recommendations are cautious and call for prospective IBD-focused research.
The structured content depth is abstract-based; Cure8 has summarized the review abstract and did not access or verify additional full-text data.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: European Union under the Health Programme of the Ministry of Investments and European Pro-jects and implemented through the Managing Authority for the Health Programme - PS/688/PS_P3/OP4/ESO4.7/PS_P3_ESO4.7_A6
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Planned synthesis of global surgical rates and outcomes in the biologics era could help clinicians, patients, and researchers understand how often surgery is needed, what types of operations are performed, and common...
People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.
Surgery remains an important treatment option for Crohn’s disease and may be considered earlier for some patients. Decisions about timing, technique, and perioperative care can affect long-term outcomes and recurrence...
